Tacrolimus Cleared for Use with MMF in Renal Transplant Patients
Astellas Pharma US, in Deerfield, Ill., has received approval for the use of Prograf (tacrolimus) in conjunction with mycophenolate mofetil (MMF) in kidney transplant recipients.
Diagnosis & Disease Information
First and Only Topical Gel for Overactive Bladder Cleared
Watson Pharmaceuticals, Corona, Calif., has received approval for Gelnique (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB).
Hyponatremia Drug Receives Marketing Clearance
The FDA has approved Samsca tablets (tolvaptan) to treat hyponatremia, one of the most common electrolyte disorders seen in hospitalized patients.
Panel Recommends Approval of Drug for Refractory Gout
The FDA’s Arthritis Drugs Advisory Committee has recommended that Krystexxa (pegloticase) be approved for treating refractory chronic gout.
Cook Medical to Market Pneumatic Lithotripter
As a result of a partnership with LMA Urology, of Gland, Switzerland, Cook Medical, of Bloomington, Ind., has added a new lithotripter to its kidney stone treatment line.
BPH Medication to Be Tested in an Extended Phase 3 Study
Æterna Zentaris Inc., of Quebec City, Canada, has announced the opening of an extended phase 3 study of cetrorelix, a treatment for benign prostatic hyperplasia (BPH).
Urine Protein May Be a Better Prostate Cancer Biomarker
DENVER—Engrailed-2 (EN2) protein is a transcription factor secreted from tumors and present in the urine of men with prostate cancer. As a result, it shows promise as a possible biomarker for the malignancy.
Cryoablation Shows Efficacy for Prostate Cancer
Treatment is associated with a low rate of biochemical recurrence and minimal urinary morbidity.
Value Funds That Can Survive the Downturn
Financial advisors divide fund managers into two broad categories, growth specialists—those who favor companies with growing earnings—and value seekers—people who aim to buy shares on the cheap.
Picking Companies that Pay Dividends
Investors looking for steady payouts should not forget to consider less well-known small stocks.
- Loading...
Loading...
Loading... 
Loading...